<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HC68DE9AA007D4A08A47816B3EAD0EB15" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 4605 IH: End Prescription Drug Ads Now Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-07-22</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4605</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250722">July 22, 2025</action-date><action-desc><sponsor name-id="N000002">Mr. Nadler</sponsor> (for himself and <cosponsor name-id="D000635">Ms. Dexter</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To ban drug manufacturers from using direct-to-consumer advertising, including social media, to promote their products.</official-title></form><legis-body id="H9C20D1C4D86E4C81985DAD79F94C5213" style="OLC"> 
<section id="H99DA18B819ED43D695A4CD6912B7D7D6" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>End Prescription Drug Ads Now Act</short-title></quote>.</text></section> <section commented="no" display-inline="no-display-inline" id="H2397A951905A41A78DD8B29042F3DBC7"><enum>2.</enum><header>Prohibition on direct-to-consumer drug advertising of drugs</header> <subsection commented="no" display-inline="no-display-inline" id="HCE9F95ED603C447FAF4EE358DBD082C9"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 502 the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block style="OLC" display-inline="no-display-inline" id="H608DD1FF72C144158688AA20275021D9"> 
<subsection id="H80C34F4119164ED49D9BD41A9378D3E8"><enum>(hh)</enum> 
<paragraph commented="no" display-inline="yes-display-inline" id="H8B4389E9CA044764997A5004802F384A"><enum>(1)</enum><text>If it is a drug approved under section 505 or licensed under section 351 of the Public Health Service Act, and subject to section 503(b)(1), and the holder of the approved application under section 505 or of the license under such section 351 has conducted direct-to-consumer advertising of the drug within the most recent 30-day period.</text></paragraph> <paragraph commented="no" display-inline="no-display-inline" id="HB35B85D7E5FD4C298DB779146D39183E" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">For purposes of this paragraph, the term <term>direct-to-consumer advertising</term>, with respect to a drug subject to section 503(b)(1), means any promotional communication targeting consumers, including through television, radio, print media, digital platforms, and social media, for purposes of marketing such a drug.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H5123AF1359C4421F817765D9E31D7AF9"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall take effect 30 days after the date of enactment of this Act, and shall apply with respect to any drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or licensed under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>), regardless of when the drug was approved or licensed.</text></subsection></section> </legis-body></bill>

